Patent ID: 8187601

Claim:
An isolated binding protein that binds human fibroblast growth factor receptor 3 (FGFR3) comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of: (a) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (15D8), a CDR Hb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18 (15D8), and a CDR H3 comprising the sequence SEQ ID NO: 19 (15D8); and (ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (15D8), a CDR L2 comprising the sequence SEQ ID NO: 23 (15D8), and a CDR L3 comprising the sequence SEQ ID NO: 24 (15D8); (b) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (27H2, 4E7(7D12)), a CDR H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 25 (27H2, 4E7(7D12)), and a CDR H3 comprising the sequence SEQ ID NO: 19 (27H2, 4E7(7D12)); and (ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (27H2, 4E7(7D12)), a CDR L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 26 (27H2, 4E7(7D12)), and a CDR L3 comprising the sequence SEQ ID NO: 27 (27H2, 4E7(7D12)); (c) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (2G4), a CDR H2 comprising the sequence SEQ ID NO: 28 (2G4), and a CDR H3 comprising the sequence SEQ ID NO: 19 (2G4); and (ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (2G4), a CDR L2 comprising the sequence SEQ ID NO: 26 (2G4), and a CDR L3 comprising the sequence SEQ ID NO: 27 (2G4); and (d) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 29 (20B4), a CDR H2 comprising the sequence SEQ ID NO: 18 (20B4), and a CDR H3 comprising the sequence SEQ ID NO: 30 (20B4); and (ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 31 (20B4), a CDR L2 comprising the sequence SEQ ID NO: 32 (20B4), and a CDR L3 comprising the sequence SEQ ID NO: 33 (20B4).